BRIEF published on 02/28/2025 at 07:35, 1 year ago ABIONYX strengthens its commitment against LCAT Deficiency Rare Disease Marketing Authorization LCAT Deficiency Biomedicine Norum Disease
PRESS RELEASE published on 02/28/2025 at 07:30, 1 year ago Inside Information / Other news releases ABIONYX renews commitment to treat LCAT Deficiency (Norum's disease) and provides updates on advances, including submission of Marketing Authorization Application and Orphan Disease Designation ABIONYX LCAT Deficiency Rare Disease Day Marketing Authorization Application Orphan Disease Designation
BRIEF published on 02/27/2025 at 19:25, 1 year ago ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024 2024 Financial Results Innovative Therapies ABIONYX Pharma Compassionate Access CRO Industry
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year ago Inside Information / Information on annual revenues ABIONYX Pharma reports €4.6m revenue and €3.2m cash at the end of Q4 2024. Details on business activities and financial performance included Revenue Cash Position Financial Update Biopharma ABIONYX Pharma
BRIEF published on 02/20/2025 at 07:35, 1 year ago ABIONYX Pharma receives €8.7 million in support for its sepsis project Financial Support France 2030 ABIONYX Pharma Sepsis Biomedicine
BRIEF published on 12/11/2024 at 12:16, 1 year 2 months ago Threshold crossing by the CDC in ABIONYX PHARMA Voting Rights CDC Threshold Crossing ABIONYX Pharma Bpifrance Participations
BRIEF published on 12/11/2024 at 12:13, 1 year 2 months ago Threshold crossing by Bpifrance in ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX
BRIEF published on 12/10/2024 at 10:51, 1 year 2 months ago Threshold crossing by Cyrille Tupin at ABIONYX PHARMA Voting Rights Actions Threshold Crossing ABIONYX Pharma Cyrille Tupin
BRIEF published on 11/14/2024 at 19:05, 1 year 3 months ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year 3 months ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
Published on 03/06/2026 at 00:00, 3 hours 56 minutes ago Redwood AI Exploring Opportunities for its Proprietary AI Platform Across Multiple Industries
Published on 03/05/2026 at 22:55, 5 hours 1 minute ago Pivotree to Release Fourth Quarter 2025 Financial Results
Published on 03/05/2026 at 20:00, 7 hours 56 minutes ago PPX Hosts Medical Outreach Campaign for Local Communities
Published on 03/05/2026 at 17:55, 10 hours 1 minute ago ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 13 hours 56 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/06/2026 at 02:00, 1 hour 56 minutes ago Hisense showcases record-breaking 116-inch UX TV at iconic winter sports venue
Published on 03/06/2026 at 00:20, 3 hours 36 minutes ago LiuGong at CONEXPO 2026 | Electric and Integrated Solutions
Published on 03/05/2026 at 19:49, 8 hours 7 minutes ago EQS-Adhoc: Northern Data Announces Preliminary Q4 2025 revenue and FY 2026 outlook
Published on 03/05/2026 at 19:15, 8 hours 41 minutes ago Huawei Wins Eight GLOMO Awards at MWC Barcelona 2026
Published on 03/05/2026 at 18:40, 9 hours 16 minutes ago 2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 9 hours 22 minutes ago Mersen: Number of shares and voting rights as of February 28, 2026
